Papp KA, et al. - An overview was illustrated in this trial with regard to the efficacy outcomes of ixekizumab therapy from three Phase 3 psoriasis studies. The data revealed rapid onset and superior efficacy of the ixekizumab therapy at both dosing regimens compared with placebo and etanercept. IXE Q2W yielded better outcomes than ixekizumab 80 mg every 4 weeks (IXE Q4W) during the first 12 weeks of treatment.